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Available online 14 January 2016Autophagy is a catabolic processwith an essential function in themaintenance of cellular and tissue homeostasis.
It is primarily recognised for its role in the degradation of dysfunctional proteins and unwanted organelles,
however in recent years the range of autophagy substrates has also been extended to lipids. Degradation of lipids
via autophagy is termed lipophagy. The ability of autophagy to contribute to themaintenance of lipo-homeostasis
becomes particularly relevant in the context of genetic lysosomal storage disorders where perturbations of
autophagic flux have been suggested to contribute to the disease aetiology. Here we review recent discoveries
of the molecular mechanisms mediating lipid turnover by the autophagy pathways. We further focus on the
relevance of autophagy, and specifically lipophagy, to the disease mechanisms. Moreover, autophagy is also
discussed as a potential therapeutic target in several key lysosomal storage disorders.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
Autophagy
Lipid metabolism
Lipid storage disorders1. Autophagy and its molecular machinery
The term autophagywasfirst described in 1966 and is translated from
Greek to mean “self-eating” [1]. There are three types of autophagy:
macroautophagy, microautophagy and chaperone-mediated autophagy
(CMA). Macroautophagy is the most well-studied pathway that involves
amultistep processwith several vesicular fusion events (Fig. 1). A nascent
autophagic vesicle (autophagosome) beginswith the formation of an iso-
lation membrane (phagophore) around the cellular component targeted
for degradation. The phagophoremembrane has been proposed in recent
years to originate from several sources including the plasma membrane,
endoplasmic reticulum (ER), mitochondria, ER-mitochondria contact
sites and the ER-Golgi intermediate compartment [2–8].The phagophore
expands and forms a double-membrane structure called autophagosome.
Autophagosomes fuse with late endosomes to form intermediate
amphisomes, which then fuse with the lysosome to form autolysosomes.
It is within the autolysosome that the lysosomal hydrolytic enzymes
degrade the autophagic cargo and release the contents into the cytoplasm
(Fig. 1). Microautophagy is the process of direct lysosomal engulfment of
cytosolic constituents or organelles in a selective or nonselective manner
(Reviewed in 9). Lastly, CMA involves the targeting of specific proteins for
degradation through the chaperone activity of heat shock cognate 70
(Hsc70) protein [10,11]. Hsc70 is able to recognise the linear peptide se-
quence KFERQ within substrates and subsequently delivers the protein. This is an open access article underto the lysosomal lumen via lysosome-associated membrane protein 2a
(LAMP2a) [12].
The core genes controllingmacroautophagy (for simplicity hereinaf-
ter referred to as autophagy) are highly conserved between yeast and
mammals. More than 37 autophagy-related (ATG) genes have been
identified in yeast [13,14]. The formation of a phagophore is a hierarchi-
cal process involving two ubiquitin-like conjugation systems, consisting
of an E1-like activating enzyme, an E2-like conjugating enzyme and an
E3-like ligase. Specifically, in one conjugation system Atg12, a
ubiquitin-like protein (UBL) is transferred from the E1-like enzyme
Atg7 [15], via an E2-like enzyme Atg10 to form a covalent attachment
with Atg5 [16]. The Atg12–5 conjugate forms a complex with Atg16
(in yeast [17]) or Atg16L1 (in mammals [18]) (Fig. 1). The second
conjugation system involves a group of UBL proteins from Atg8 (in
yeast [19]), or the mammalian Atg8-like family of proteins, comprised
of microtubule-associated protein light chain 3 (LC3), as well as
Gamma-aminobutyric acid receptor-associated protein (GABARAP)
and Golgi-associated ATPase enhancer of 16 kDa (GATE-16) proteins
[20]. Using LC3 as an example, first it is modified at the C-terminal by
Atg4B to become LC3-I [15,20]. In two subsequent reactions with Atg7
and then Atg3, an E2-like enzyme, the LC3-I is conjugated with
phosphatidylethanolamine (PE) to form LC3-II [20] (Fig. 1). The
Atg12-Atg5-Atg16L1 complex and LC3-II participate in the formation
of phagophores and the initiation of autophagy. As the phagophore is
completed to form an autophagosome, the Atg12-Atg5-Atg16L1
complex is removed from the autophagic membrane whereas LC3-II
remains attached to the inner membrane (it is removed from thethe CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Regulation of autophagy: Deprivation of growth promoting stimuli (growth factors, amino acids, ATP) activates autophagy via mTORC1 and AMPK signalling pathways which
regulate biogenesis of autophagosomes. Macroautophagy can also be activated via mTOR-independent pathways. Conjugation systems (top right insert) promote formation of
lipidated membrane-bound LC3-II on nascent autophagosomal membranes which engulf autophagic cargoes leading to the formation of autophagosomes. Fusion events between
autophagosomes and endosomes result in the formation of amphisomes which mature into autolysosomes following fusion with lysosomes. Autolysosomes (which may also form by
direct fusion of autophagosomes with lysosomes) are digestive organelles where acid hydrolases degrade autophagosomal substrates followed by the efflux of degraded material into
cytoplasm.
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autolysosomes by lysosomal hydrolases [21] (Fig. 1). There is crosstalk
between the two conjugation systems as the Atg12-Atg5-Atg16L1
complex has E3-like ligase activity towards the formation of LC3-II
[22]. Knockout of essential autophagy genes, such as Atg5 or Atg7,
prevents the formation of phagophores and autophagosomes, and are
thus employed to model autophagy-deficient conditions [23,24].
Fusion between late endosomes and autophagosomes to form
amphisomes generally precedes the final fusion with lysosomes and
the generation of autolysosomes [25–27]. There are several mediators
of these vesicle fusion events, such as Rab7, UVRAG, Beclin-1, hVps34,
hVps15 and SNARE proteins. Rab7 was identified to play a role in the
fusion of late autophagic vacuoles but it was not required for the earlier
fusion events between early autophagosomes and endosomes [28].
Beclin-1, Vps34 and Vps15 form a core complex with different roles
depending on whether they are bound to Ambra1 and Atg14L, Bif-1
and UVRAG or UVRAG and Rubicon [29–31] (Fig. 1). If the core complex
is associatedwith Ambra1 and Atg14L then autophagosomematuration
is promoted [32,33]. UVRAG has roles in promoting autophagosome
formation, maturation and endosomal fusion through interactionswith the core complex [34]. When Rubicon is bound to the core complex
alongside UVRAG, autophagosome and endosome maturation is
inhibited [31,32]. In addition, SNARE (SNAP (Soluble NSF Attachment
Protein) Receptor) proteins regulate membrane tethering and fusion,
events in the autophagic pathway [35]. Recent studies have identified
an autophagosomal SNARE, Syntaxin-17 which forms a complex with
Atg14 and the SNARE, SNAP-29 to facilitate binding to the late
endosomal/lysosomal SNARE, VAMP8 and thus promote autophagosome
maturation [36,37]. Interestingly, a non-canonical, alternative autophagy
pathway has been described which uses the same basic autophagy
machinery, such as ULK1 and Beclin 1, but is Atg5-, Atg7- and LC3-
independent [38–40].
Various intracellular signalling pathways act upstream of the
autophagic machinery to regulate the autophagy process, these are
discussed below.
2. mTOR-dependent regulation of autophagy
The classical regulator of autophagy is the mTORC1 (mammalian or
mechanistic Target of Rapamycin Complex 1) pathway, which was first
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protein exists in two functional, multimeric complexes, mTORC1 and
mTORC2, where mTORC2 is generally considered to be important in the
regulation of cellular metabolism and the cytoskeleton. mTORC1, on the
other hand, functions to integrate a wide range of intra-and extracellular
anabolic and catabolic signals to control protein synthesis, metabolism
and promote cellular, organ and organismal growth [43–45]. The
mTORC1 complex consists of the scaffolding subunit raptor (regulatory
associated protein of mTOR), the kinase inhibitors DEPTOR (DEP domain
containing mTOR-interacting protein), PRAS40 (proline-rich Akt
substrate of 40 kDa), mLST8 (mTOR associated protein) and the protein
kinase mTOR [43]. mTORC1 activity is regulated by the availability of
intracellular nutrients, energy, oxygen and growth factors; sufficiency
promotes mTORC1 activation and phosphorylation of downstream
targets including the protein translation regulators, S6K1 (p70-S6 Kinase
1) and the eukaryotic initiation factor 4E (eIF4E) binding protein 1
(4E-BP1) [43], while at the same time inhibiting autophagy. Deprivation
of any mTORC1-promoting signals leads to the activation of autophagy
and inhibition of anabolic processes [43,46]. Autophagy is induced during
energy or nutrient stress to recycle intracellular components, restore the
deficiency and promote cellular survival.
2.1. Regulation of autophagy downstream of mTORC1
Several mechanisms by which mTORC1 regulates autophagy have
been described. Firstly, under nutrient-rich conditions,mTORC1directly
interacts with the ULK1-Atg13-FIP200 complex and phosphorylates
ULK1 and Atg13 which inhibits autophagy. Upon inactivation of
mTORC1, ULK1 and Atg13 are dephosphorylated which relieves inhibi-
tion of autophagy [47–49]. Secondly, mTORC1 phosphorylates and
thereby inactivates DAP1 (death-associated protein 1) and it was
suggested to act as a braking system for autophagy [50]. Thirdly,
mTORC1 phosphorylates TFEB (transcription factor EB), which prevents
its translocation to the nucleus and inhibits the transcription of autoph-
agy and lysosomal related genes [51]. Finally, an mTORC1-dependent
post-transcriptional regulatory pathway of autophagy via Dcp2 was
identified. In nutrient-rich conditions, DDX6 (a RCK family member)
recruits many ATGmRNA transcripts to the Dcp2 decapping complex,
leading to mRNA degradation and autophagy inhibition, whilst
starvation-dependent dephosphorylation of Dcp2 reverses the process
[52]. These pathways combined orchestrate autophagy signals down-
stream of mTORC1.
2.2. Regulation of autophagy upstream of mTORC1
A prerequisite signal for mTORC1 activity is the availability of amino
acids which promote the translocation of the complex to the cytoplas-
mic surface of lysosomes, thus bringing it into close proximity with its
activator, the small GTPase, Rheb [53,54]. How amino acids activate
mTORC1 is not fully understood but amino acids have been shown to
signal via a heterodimeric complex of Rag GTPases, whereby the
functionally redundant RagA or RagB forms a complex with RagC or
RagD [55] (Fig. 1). The amino acid-dependent nucleotide loading of
RagA/B with GTP and RagC/D with GDP promotes the activity of
mTORC1 [56]. This nucleotide loading is controlled by a number of
regulatory protein complexes [54,57].
Another mechanism of amino acid sensing is mediated by the TSC
complex, which consists of three subunits, TSC1, TBC1D7 and TSC2
and which is also regulated by other inputs, including growth factors,
via PI3K and Akt [58–60]. The TSC2 subunit of the complex acts as a
GTPase activating protein (GAP) for Rheb, promoting the hydrolysis of
GTP to GDP and thereby inhibiting its ability to activate mTORC1 [61].
Starvation has also been shown to promote lysosomal recruitment of
TSC complex and [62] (Fig. 1). In addition to amino acids and growth
factors, mTORC1 activity can be regulated by the cellular energy state
through the AMP-dependent kinase (AMPK) which is activated by lowlevels of ATP in the cell and regulates autophagy via TSC complex [63]
and via ULK1 complex which promotes autophagosome biogenesis
[64] (Fig. 1).
mTORC1 is an appealing pharmacological target to manipulate au-
tophagy which encouraged great efforts to develop better and more
specific inhibitors [65]. Rapamycin is the best known mTOR inhibitor
[66], but many rapamycin analogues (rapalogs) have been developed
and are in clinical trials.
3. mTORC1-independent regulation of autophagy
In addition to the canonical mTORC1-dependent regulation of
autophagy, several mTOR-independent pathways have been described.
The main mTORC1-independent mechanisms are mediated by intracel-
lular inositol [67], calcium [68,69], cAMP [68] and the JNK1/Beclin1/
PI2KC3 signalling pathway; reviewed elsewhere [70]. Type III PI3 kinase
is an important regulator of autophagosome biogenesis and several
mTOR-independent signalling cascades, including MAPK-ERK1/2,
Stat2, Akt/Foxo3 and CXCR4/GPCR, converge into this PI3K signalling
node [71].
Several small molecules that induce autophagy have been
described, although their mechanism of action is not always
known. For example, trehalose efficiently clears autophagic cargo
in an autophagy-dependent, but mTORC1-independent manner
[72]. Also, a comprehensive screen of small molecules identified
many mTOR-independent small molecule enhancers (SMERs) of
autophagy [73]. These and other mTORC1-independent autophagy
enhancers have potential therapeutic applications in diseases with
perturbation of lipid or protein homeostasis, such as neurodegener-
ative and lipid storage disorders; reviewed elsewhere [27,70,74,75].
4. An introduction to lipophagy
Despite the classical view that autophagy is a largely bulk, nonselec-
tive process, it is being increasingly recognised that there is in fact a re-
markable selectivity in the nature of cargo degraded. For instance,
through unique organelle-specific adaptors the autophagy pathway is
capable of sequestering damaged or aged organelles, oxidised proteins,
and even portions for the cytosol, which are then degraded in
lysosomes. Accordingly, the selective degradation of endoplasmic
reticulum, mitochondria, ribosomes, and peroxisomes are referred to
as ERphagy [76], mitophagy [77], ribophagy [78] and pexophagy [79],
respectively.
We have previously shown that cellular lipid stores are also
targeted for lysosomal degradation via a process termed “lipophagy”
[80]. The identification of lipophagy as a new process dedicated to
cellular lipid removal has mapped autophagy as an emerging player
in cellular lipid metabolism [81]. Indeed, a number of studies have
now demonstrated roles for autophagy in lipid droplet (LD) turnover
in cells as diverse as hepatocytes [80,82], hypothalamic [83] and
striatal neurons [84], glial cells [84], macrophage foam cells [85],
enterocytes [86], T cells [87], fibroblasts, adipocytes and adipose-
resident macrophages [88], prostate carcinoma cells [89], as well as
in Saccharomyces cerevisiae [90], Caenorhabditis elegans [91], certain
fungal species [92], and in staple crop such as rice [93]. It is likely that
activation of lipophagy in each of these cell types is context-specific
and coupled to energetic requirements to perform a certain function.
For instance, lipophagy is acutely activated in livers during fasting to
rapidly degrade the large lipid bolus delivered from the adipose tis-
sue [80]. On the other hand, hypothalamic neurons employ
lipophagy as a means to generate free fatty acids that boost levels
of agouti-related peptide (AgRP) [83], a neuropeptide that stimu-
lates feeding by activating second-order neurons in the hypothala-
mus. Similarly, lymphocytes require lipophagy to generate the
energy necessary for their activation in response to antigenic
challenges [87]. Although the upstream signals activating lipophagy
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nents and the mechanism(s) of lipophagy activation are conserved
in most cell types. Thus, the ubiquitous nature of lipophagy is a tes-
tament to the fact that cells, tissues, and species have evolved with
a mechanism in place to counteract excessive lipid build-up or to
rapidly utilise lipid reserves for specialised functions.
All cells store lipids during times of nutrient sufficiency in the form
of lipid droplets (LDs). When nutrients are scarce, cells rapidly deplete
their energy reserves, including LDs, in order to meet their basic ener-
getic needs. Physiological fat storage occurs in cytoplasmic LDs. An LD
is, in essence, an organelle consisting of a neutral lipid core of triglycer-
ides and cholesteryl esters that is limited by a phospholipid monolayer
and a family of unique LD coat proteins, now classified as perilipins
(PLINs) [94]. Each LD ranges from 0.1 to 10 μm in size, however cells
that specialise in fat storage, for instance adipocytes, may have LDs
that are 10–100 times larger. It is well-established that neutral lipases,
adipose triglyceride lipase (ATGL) [95], hormone-sensitive lipase
(HSL) [96] and monoacylglycerol lipase (MGL) [97] act in tandem to
rapidly mobilise fat droplets during nutrient deprivation. During lipoly-
sis, which is best characterised in the adipocyte, activation of protein
kinase A leads to the phosphorylation and proteasomal degradation of
perilipin 1 (PLIN1) [98]. This results in the release of comparative
gene identification-58 (CGI-58) which then activates ATGL and initiates
triglyceride breakdown [99], as discussed in subsequent sections.
Together, this process allows lipases to dock upon and consume the
exposed LD core. Conversely, G0/G1 switch 2 (G0S2) protein inhibits
ATGL [100]. Since starvation leads to activation of lipolysis and
autophagy, we envisioned a possible role for autophagy in the turnover
of LDs.
In cultured hepatocytes and mouse embryonic fibroblasts, chemical
and/or genetic inhibition of autophagy resulted in increased LD number
and size [80]. Conversely, activation of autophagy by rapamycin in-
creased the colocalisation of the LDmarker, BODIPY with the lysosomal
marker (LAMP1) indicating activation of lipophagy. Furthermore,
autophagosome and lysosome fractions from fasted mice both
contained LD-associated PLINs, and liver-isolated LDs co-purified with
autophagosome marker LC3-II [80]. Moreover, liver-specific Atg7
knockout mice displayed large livers that were accumulating cellular
debris, including damaged organelles, ubiquitinated proteins, and a sig-
nificant increase in lipid content [80]. Histological analyses revealed
that livers lacking Atg7 closely resembled those observed in cases of
human non-alcoholic fatty liver disease, thus underscoring a critical
role of this pathway in hepatic lipo-homeostasis. Together, these results
demonstrate a fundamental role for autophagy in cellular lipid
utilisation [80].
4.1. Mechanisms of lipophagy
The mechanisms regulating lipophagy, in particular those related to
how autophagy selectively identifies and sequesters LD, remain un-
known. While the search for the elusive lipophagy adaptor continues,
it has been suggested that lipophagy entails complete or “piecemeal”
consumption of LD by autophagosomes [80] (Fig. 2). In the course of
our studies, we observed that isolated LDs from fasted mice displayed
enrichment of both cytosolic LC3-I and autophagosome-bound LC3-II
which suggested that the conversion of LC3-I into LC3-II occurs at the
surface of LDs [80]. Indeed, our unpublished in vivowork, and recently
published in vitro work from the Cuervo group [101] indicate that, in
fact, several regulatory autophagy proteins are enriched in LDs. This
would support the idea that de novo biogenesis of autophagosomes to
sequester LDs occurs at the LD surface. It is interesting to note at this
point that the lipase, PNPLA5has been shown to be required for efficient
autophagy of diverse form of substrates [102]. In a more recent study,
Shpilka et al. have identified that in yeast, enzymes required for synthe-
sis of triglycerides (Dga1 and Lro1) or steryl esters (Are1 and Are2), as
well as the lipase Ldh1 are required for autophagy [103]. These studiesindicate that active lipid metabolism at the LD surface or at LD-ER
contact sites provide the metabolic energy required for the de novo
formation of autophagosomes [102,103].
Rambold et al. recently demonstrated that acutely starved cells use
LDs to supply mitochondria with fatty acids for β-oxidation (break
down of fatty acids to generate acetyl-CoA). Interestingly lipase activity
was necessary for fatty acid delivery from LDs into mitochondria [104].
Bulk autophagy, but not lipophagy was shown to be involved in
shuttling cellular membrane-derived fatty acids into the cytoplasm
and their association with LDs, which was required for mitochondrial
oxidative metabolism [104]. In our view, it would appear that locally
generated free fatty acidsmade available by lipases and rapidly oxidised
in the mitochondria are likely to sustain an active feed-forward
mechanism tomaximise LD breakdown through de novo autophagosome
formation. Indeed, it was suggested that LDs could be mobilised into
phospholipids necessary for autophagosomal membrane formation and
growth whilst PNPLA5, a neutral lipase that localises to lipid droplets,
was needed for optimal initiation of autophagy [102].
Given these complex cellular dynamics, it is not surprising to note
that the cellular components that generate the membranes to form
autophagosomes, e.g., ER or mitochondria [6] are the very substrates
that are eventually devoured by the autophagic machinery.
Regarding the mechanistic basis for the regulation of lipophagy, an
important question is how does the autophagic machinery recognise
LDs as a substrate?While polyubiquitin chains of specific lysine linkages
are a well-established coding system to distinguish proteins and
organelles intended for degradation, it remains unclear whether
polyubiquitination could also serve to tag and degrade LDs. On that
note, ancient ubiquitous protein (AUP1) is a protein that has been
shown to localise to LDs and interact with an E2 ubiquitin-conjugating
enzyme, Ube2g2. It is possible that the AUP1-Ube2g2 complex tags LD
components for degradation [105]. However, since it is well known
that LDs serve as a cellular buffer that sequesters and inactivates critical
proteins, for instance a subset of histone proteins are sequestered by
LDs during development [106], it would require further work to deter-
mine whether AUP1-Ube2g2 complex indeed labels LDs for degrada-
tion. The second relevant question here is whether crosstalk between
different proteolytic systems regulates turnover of LD components
and whether lipophagy is involved? A study using Chinese hamster
ovarian cells has shown that PLINs are stabilised and prevented from
degradation when cells are treated with fatty acids [107]. By contrast,
PLINs were observed to be rapidly degraded when triglyceride
biogenesis was blocked [107]. In addition, PLINs were found to be
polyubiquitinated and selective proteasomal inhibitors blocked PLIN
degradation, indicating that the proteasome participates in their
turnover [107].
4.2. Role of CMA in lipophagy
Interestingly, recent work from the Cuervo group has identified
that chaperone-mediated autophagy (CMA), may also play a signifi-
cant role in selective degradation of PLINs such as PLIN1 exclusively
expressed in adipocytes and PLIN2 and PLIN3 expressed ubiquitously
[101] (Fig. 2). Lamp2A knockout mice showed pronounced hepatic
steatosis, coupled with insulin resistance [108]. The fact that LDs ac-
cumulate in a CMA-deficient model is intriguing since 1) macro- and
micro-autophagy are functional in this model, and in fact LAMP-2A
KO mice display a compensatory upregulation of macroautophagy
in vitro and in vivo, and 2) only proteins and not lipids can be CMA
substrates. This led to their hypothesis that CMA is required to elim-
inate LD coat proteins, e.g., PLINs as a prerequisite for lipolysis to
occur. The authors show unequivocally, that PLIN2 and PLIN3 are
CMA substrates and that their degradation increases in conditions
of increased lipolysis, e.g., during starvation [101]. Since PLINs are
gatekeepers of LD mobilisation, the inability to degrade them in the
CMA-deficient model systems, results in LD accumulation and
Fig. 2.Autophagy degrades lipid droplets: A— LC3-II positivemembranes engulf small lipid droplets or sequester portions of large lipid droplets. Autophagosomes deliver the lipid cargo to
lysosomes wherein acid hydrolases degrade lipids. Fatty acids are released into the cytosol and these undergo mitochondrial β-oxidation for provision of energy. B — Activation of
chaperone-mediated autophagy degrades the lipid droplet coat proteins PLIN2 and PLIN3 through coordinated action of Hsc70 and the LAMP-2A receptor. Consequently, the lipid
droplet surface becomes accessible to cytosolic lipases, e.g., ATGL that hydrolyzes the lipid droplet resident triglycerides to generate free fatty acids, and the autophagicmachinery proteins.
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surface occurs prior to the docking of autophagy proteins and cyto-
solic lipases [101] (Fig. 2). In vitro and in vivo studies, including live
cell video-microscopy, show decreased association of autophagy
proteins and LAMP1 with LDs in the CMA-null cells. Moreover,
over-expressing a PLIN2 mutant lacking a functional CMA-targeting
motif, KFERQ, in wild-type cells was sufficient to prevent its
degradation and block the association of cytosolic lipases and
autophagy effector proteins with LDs [101]. Therefore, functional
CMA is essential for removal of LD proteins from specific areas of
the LDs, which in turn ‘primes’ these regions for the recruitment of
the lipolytic machinery – lipases and autophagy proteins. The
authors further go on to suggest that phosphorylation of PLIN2 is
important for its recognition and degradation via CMA opening
thus a new area of exploration in the understanding of the first
trigger for LD turnover.4.3. Receptor proteins in lipophagy
While CMA and the proteasome degrade LD coat proteins, it could
also be possible that selective autophagy per se contributes to elimina-
tion of LD proteins. Over the last few years, a number of distinct selec-
tive autophagy receptors have been identified, e.g., SQSTM1/p62 [109],
NDP52 [110], optineurin [111], and NBR1 [112] to mention a few, and
it is quite possible that any of these could also serve as the LD receptors.
Finally, another protein of interest that could serve as a possible cargo
recognition receptor is Huntingtin. Huntingtin was recently shown to
act as a scaffold for selective autophagy [113] and mutations in
Huntingtin have been shown to lead to the generation of large, empty
autophagosomes that fail to sequester cargo [114]. Since cells express-
ing mutant Huntingtin have revealed remarkable lipid accumulation
[114], it could be possible that Huntingtin is a LD recognition receptor
protein. Finally, an intriguing possibility is that LC3 can recognise and
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teraction during mitophagy [115]. Further studies will be necessary to
validate these hypotheses and uncover the molecular mechanisms of
how the autophagic apparatus degrades LDs.
5. Lipophagy in fatty liver disease
Acute fatty acid exposure results in the activation of autophagy in
cultured hepatocytes [80] and in neurons [83]. This autophagy activa-
tion likely serves to eliminate LDs generated from the rapid influx of
lipids into the cell. In contrast, prolonged lipid exposure, e.g. when
mice are fed a high fat diet, results in the suppression of autophagy
and lipophagy as noted by decreased LD-associated LC3 and decreased
areas of degradation in LD [80]. It has also been reported that levels of
the E1-like ligase, Atg7 are diminished in high fat diet-fed mice and in
the leptin-deficient ob/obmouse model [82]. This reduction may con-
tribute, at least in part, to the autophagy suppression observed during
chronic over-nutrition. In addition to depletion of Atg7 protein levels,
a number of factorsmay contribute to suppression of autophagy. For in-
stance, obesity is associated with hyper-activation of mTORC1 signal-
ling which is a well-established inhibitor of autophagy. On the other
hand, it has been shown that a prolonged high fat diet not only blocks
the fusion of autophagosomes and lysosomes [116], but inhibits CMA
[117]. Given the recent elucidation of the selective role for CMA in the
degradation of LD proteins, it is conceivable that blockage of autophagy
and CMA could bear a strong inhibitory effect on LD breakdown by
lipophagy. Given these bearings, it is quite likely that suppression of
autophagy and lipophagy following chronic over-nutrition will set up
a vicious cycle that will, in turn, promote lipid accumulation and
metabolic compromise.
Accumulation of fat begets inflammation, and Yang et al. have
shown that high fat-induced autophagy suppression is associated
with the development of hepatic inflammation and endoplasmic re-
ticulum stress [82], while in contrast, liver-specific overexpression of
Atg7 restores autophagy and ameliorates hepatic steatosis in these
models [82]. Similarly, other studies have revealed that hepatocytes
deficient in autophagy are susceptible to cell death from oxidant
stress [118], and that lipophagy, in fact, ordinarily provides the
fatty acid substrates that are oxidised to generate the energy and
prevent cell death [118]. In addition, fat-laden and inflamed livers
produce tumour necrosis factor (TNF)-α and recent work from the
Czaja laboratory has shown that inhibiting autophagy predisposes
livers to severe hepatotoxicity from TNF-α and galactosamine
[119]. Furthermore, overexpressing an essential component of the
Class III PI3K complex, Beclin1, prevents hepatotoxicity in response
to tumour necrosis factor [119]. In addition to these mechanisms, it
cannot be excluded that lipophagy detoxifies the liver by eliminating
cytotoxic lipid species such as sphingolipids and ceramide generated
during obesity. Thus, defective autophagy in the background of
hepatic steatosis could be the “second hit” in the proposed “two-hit
theory” that defines the pathobiology of a normal liver becoming
steatotic and then progressing to non-alcoholic steatohepatitis
[120]. These results also provide proof of concept that activating
autophagy, and specifically lipophagy, could be a novel strategy
against obesity-associated fatty liver disease and development of
steatohepatitis. Underscoring the necessity of lipophagy in main-
taining hepatic lipo-homeostasis is the fact that livers remain
vulnerable to steatosis due to their central role in handling lipid
flux, and since lipases ATGL and HSL, which control lipolysis in
adipose tissue, are poorly expressed in the liver [95,121]. In this
respect, it has been shown that in cells that are lacking ATGL and
HSL, lipophagy is not induced, but the lack of free fatty acids for
energy production can be compensated for by upregulation of
autophagy [122]. Whether activating autophagy and specifically
lipophagy is a viable therapeutic option in treating human fatty
liver disease it remains to be seen in the years to come.6. Lysosomal lipid storage diseases
Lysosomal lipid storage disorders are a group of rare inherited
diseases that cause accumulation of lipids in the lysosomes of cells
that leads to cellular toxicity [123,124]. Neurons are particularly
sensitive to lipid accumulation and therefore patients normally exhibit
neurodegeneration often with stunted brain development. Many of
these diseases are fatal at a young age and treatment options are limited.
Autophagy has been identified as a major pathway for the metabolism
of lipids in cells [80]. Perturbations in autophagy, or specifically
lipophagy, could thus be linked to the accumulation of cellular lipids
in patients with lipid storage disorders. Although there is growing
evidence for the role of autophagy in lipid storage disorders (see
Table 1), further investigation is required to fully understand the
mechanisms and investigate the therapeutic potential of targeting
autophagy in these diseases.
6.1. GM1 gangliosidosis
GM1 gangliosidosis is a rare lysosomal storage disorder that clinical-
ly exists in three forms based on the age of onset. Type I (early infantile
form) occurs before 6 months of age with a high risk of death. It is
characterised by psychomotor regression, central nervous system
defects and musculo-skeletal abnormalities [125,126]. Type II (late
infantile or juvenile form) presents between 7 months and 3 years of
age and is associated with ataxia, dwarfism and neurodegeneration
[127]. Type III (adult form) is least symptomatic, and can occur
anywhere between 3 and 30 years with muscle malfunction [127,128].
GM1 gangliosidosis is caused by mutations in the GLB1 gene, which
leads to deficiency in the activity of lysosomal β-galactosidase [129] and
an accumulation of lipids such as GM1 ganglioside. The nervous system
of patients is the most severely affected area [130–132]. Although it is
not entirely clearwhether perturbation in autophagy is underlying clin-
ical features of GM1 gangliosidosis, accumulation of autophagosomes
(LC3-II) was found in the cortex and hippocampus in a mouse model
of GM1 gangliosisosis (β-galactosidase deficient βGal−/− mice) [133,
134]. Despite the fact that autophagic flux data were not reported in
this study, the elevation in LC3-II levels was shown to be independent
of mTOR activity [134]. This is possibly indicative of impairment in
autophagic flux arising due to inhibition of autophagosome maturation
rather than increased synthesis.
Presently, there are only symptomatic treatments for the disease
with no effective cure. However, there have been some promising
results from in vitro studies and animalmodels. Addition of the chemical
chaperone N-octyl-4-epi-β-valienamine (NOEV) to cultured human
and mouse fibroblasts rescued the disease phenotypes [135]. In
addition, when NOEV was administered to mice that express the
mutated human β-galactosidase that causes Type II GM1 gangliosidosis
it decreased GM1 accumulation in the cerebral cortex and brainstem
[135]. Another potential therapeutic treatment option being explored
is the use of adenoviral associated virus gene delivery of βGal, which
improved lysosomal storage clearance in nervous tissue and increased
lifespan in βGal−/−mice [136].
6.2. Fabry disease
Fabry disease (FD) is a rare, inherited, metabolic disorder with clin-
ical manifestations including lipid accumulation in the cornea [137],
heart defects, angina and exercise intolerance [138–141]. It is more
common in males than females, and is caused by mutations in the
gene encoding ɑ-galactosidase A located on the X-chromosome
[142–145]. Without functional ɑ-galactosidase A, cells accumulate
globotriaosylceramide and other glycosphingolipids in various tissues
including the kidney [123,124]. This is associated with defective
autophagy since increased levels of LC3 and p62, and accumulation of
vacuoles, where found in renal cells from FD patients compared to the
Table 1
Disease related mutations and their effect on the autophagy pathway.
Disease Gene Protein Function Lysosomal accumulation Deregulation in autophagy Reference
Fabry disease GLA alpha-galactosidase A Homodimeric glycoprotein, hydrolyses
glycolipids and glycoproteins
Failure to catabolise
alpha-D-galactosyl glycolipid
moieties
Inhibition caused by disruption of
autophagy-lysosome pathway
[142],
[146]
Gaucher disease GBA glucosidase, beta, acid Lysosomal membrane protein,
Involved in glycolipid metabolism
Accumulation of glucocerebrosides Block in autophagic flux [154],
[160]
Glycogenoses GAA acid alpha-glucosidase Lysosomal enzyme, converts glycogen to glucose Glycogen accumulation Accumulation of autophagosomes [174],
[176]
GM1 Gangliosidosis GLB1 β-galactosidase Lysosomal enzyme, hydrolyzes
beta-galactose from ganglioside substrates
Accumulation of GM1 gangliosides Accumulation of autophagosomes [128],
[134]
Mucopolysaccharidoses More than 10
genes identified
Lysosomal enzymes Glycosaminoglycans Defective autophagosome-lysosome
fusion
[178]
Mucolipidoses
ML IV (Gangliosidose) MCOLN1 Mucolipin 1 Cationen channel receptor protein, regulation of
lysosomal exocytosis
Deficiency of transport channel
receptor protein
Impairment of autophagy [227]
Neuronal Ceroid-Lipofuscinoses
CLN3 Battenin Role in pH homeostasis and Catepsin
D function
Accumulation of ceroid lipofuscin Disruption of autophagy vacuole
maturation and impaired mitophagy
[239],
[241]
CLN6 non-glycosylated endoplasmic reticulum
(ER)-resident membrane protein
Likely to be involved in the degradation of
post-translationally modified proteins
Protein accumulation Accumulation of autophagic vacuoles [243]
Niemann–Pick disease
Type A and B SMPD1 ASM (Acid sphingomyelinase) Enzyme, conversion of sphingomyelin to
ceramide
Accumulation of sphingomyelin Inefficient autophago-lysosomal
clearance
[188],
[200]
Type C NPC1 (95%)
NPC2 (5%)
NPC1, NPC2 Cholesterol export from late
endosomal/lysosomal compartment
Accumulation of cholesterol Defective amphisome formation [187],
[196],
[195]
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and LAMP-1 along with aberrant accumulation of phosphorylated
α-synuclein was found in the brain sections of ɑ-galactosidase
A-deficient mice [147]. Additionally, knockdown of ɑ-galactosidase A
by lentiviral shRNA in human renal cells increased LC3-II levels but
was associated with downregulation of mTOR and AKT activity [148].
Although this study may be indicative of an induction of autophagy,
accumulation of autophagic substrates reported in other studies with
patient cells points towards impairment in autophagic flux; however,
mechanistic details are yet to be addressed.
Interestingly, enzyme replacement therapy (ERT) in patients for
3 years with the drug, agalsidase alfa, reduced the staining intensity of
LC3-II and p62, and the vacuolar phenotype, indicating that the defect
in autophagic flux could possibly be restored after introduction of the
functional human ɑ-galactosidase A [146]. Several treatment options
have been employed to treat FD in the last few decades. ERT was tested
in two patients using healthy donor plasma which contained the
missing enzyme [149]. Two recombinant versions were used in a 30–
36 month trial which resulted in a reduction of globotriaosylceramide
concentration in the blood. [150]. Since 2001 agalsidase alfa has been
available for treatment in patients [151]. Production of recombinant
enzymes is prohibitively expensive and its cost effectiveness compared
to the benefits to the patients is debatable [152]. Additional
investigation into a role for autophagy in FD is warranted, as chemical
modulation would be more economically viable than ERT.
6.3. Gaucher's disease
Gaucher's disease (GD) is the most common inherited lysosomal
storage disorder. The disease symptoms include hepatomegaly, spleno-
megaly, haematological disorders, skeletal weakening and conjunctival
degeneration [153]. There are three clinical subtypes: type I (non-neu-
ropathic, adult form), type II (acute neuropathic, infantile form) and
type III (chronic neuropathic, juvenile form). Mutations in the gene
encoding glucosylceramidase (also known as glucocerebrosidase) that
diminish or eliminate the activity of this enzyme is the underlying
cause of GD [154]. Deficiency in glucosylceramidase causes the accumu-
lation of glucosylceramide in cells that can lead to cytotoxicity [155].
Deficiency of another lysosomal protein, Saponin C, which is an enhanc-
er of glycosphingolipid hydrolase activity of glucosylceramidase, leads
to a variant form of GD with accumulation of glucosylceramide in the
macrophages and central nervous system. In types II and III, the disease
pathology displays accumulation of lipids, inclusions and cell death in
neurons, which has been recapitulated in transgenic models in vivo,
such as inGbaflox/flox; nestin-Cre [156] and PSAP−/− (genewhich encodes
for precursor of Saponin C) mice [157].
Studies in mouse models of GD indicate there may be defects in
autophagy. Accumulation of ubiquitinated protein aggregates, insoluble
α-synuclein, lysosomes as well as autophagic substrates such as p62
occurs in the brain of transgenic mice with glucosylceramidase or PSAP
deficiency [157–159]. In addition, accumulation of dysfunctional
mitochondria due to defective mitophagywas found in neurons and as-
trocytes in a mouse model of GD (gba−/−) [158]. Likewise, impaired
degradation of autophagosomeswas seen in Saponin C-deficient patient
fibroblasts. This was suggested to arise due to a block in autophagic flux
caused by diminished activity of the lysosomal enzymes, cathepsins B
and D [160]. In this system, over-expression of functional lysosomal
hydrolases restored the degradative capability of the autolysosomes
[160]. A recent study has demonstrated that a block in autophagic flux
arising due to impaired autophagosome maturation in neuronal cells
derived from GD patient-specific induced pluripotent stem cells
(iPSCs) [161]. Furthermore, downregulation and reduced stability of
the transcription factor EB (TFEB; the master regulator of lysosomal
genes [162]), as well as a reduction in lysosomal gene expression, was
found in GD iPSC-derived neurons. In this study, treatment of mutant
neuronal cells with recombinant glucocerebrosidase abrogated thelysosomal dysfunction and autophagy block; an effect enhanced by
overexpression of TFEB but not with TFEB alone, without the recombi-
nant enzyme [161].
ERT has been developed for the treatment of GD [163]. There are
three enzyme replacement drugs: Imiglucerase [164], Velaglucerase
alfa [165] and Taliglucerase alfa [166]. All these drugs are recombinant
versions of glucocerebrosidase that have slightly different pharmaco-
logical properties [167,168]. Another option for treatment is substrate
reduction therapy, such as with Eliglustat tartrate that functions by
blocking the activity of glucosylceramide synthase, the enzyme which
catalyses the production of glucosylceramide [168,169]. This drug was
shown to be safe for human intake in phase 1 clinical trials [170] and
was further demonstrated to reduce the levels of ganglioside GM3 and
glucosylceramide in phase 2 trials [171,172]. However, ERT is extremely
expensive and thus justifies the search for other therapeutic targets
[173]. Although the potential for autophagy modulation has not been
investigated rigorously, a recent study in GD iPSC model has reported
neurotoxicity caused by treatment with rapamycin [161].
6.4. Glycogenoses
Glycogenoses are a group of diseases caused by defective metabo-
lismor degradation of glycogenwhich results in its accumulationwithin
enlarged lysosomes. Glycogenoses disorders include Pompe disease,
Von Gierke disease and Her's disease among others. Pompe disease is
caused by a deficiency or absence of the lysosomal enzyme, acid
alpha-glucosidase (GAA) which prevents glycogen conversion to
glucose. ERT has had therapeutic success in treating the cardiac defects
characteristic of Pompe disease however other disease symptoms
persist in the other major site of clinical manifestation, skeletal muscle
tissue (reviewed in 174). It has been postulated that disease persists
as a result of the general defect in membrane trafficking seen within
Pompe models and patients. As a result, there is an accumulation of
autophagosomes (as a result of significantly reduced lysosomal fusion
[175] and associated p62 and ubiquitin inclusions all of which
contribute to cellular toxicity [161,176]. Furthermore, a build-up of
lipofuscin within accumulated vesicles and in the cytoplasm further
perturbs membrane trafficking and mitochondrial turnover which
may cause defective redox balance in the cells [174]. The resulting
accumulation of cellular contents causes cell toxicity and perturbs
muscle cell integrity, contractile function and survival and leads to the
muscle weakening observed in Pompe disease mouse models and pa-
tients. Inhibition of autophagy is currently being explored as a potential
therapeutic intervention in Pompe disease. Skeletal muscle-specific
knock-out of Atg5 and Atg7 leads to reduced glycogen delivery and
therefore accumulation in the lysosome (instead it is metabolised safely
in the cytoplasm) and increased lysosomal delivery of ERT (which is
normally perturbed in muscle because of the defects in membrane
trafficking to lysosomes) [161,177]. These studies suggest that targeting
autophagy may provide benefits to Pombe disease aetiology.
6.5. Mucopolysaccharidoses
Mucopolysaccharidoses and the related, multiple sulfatase
deficiency (MSD) are group of diseases characterised by defective
degradation of glycosaminoglycans (GAGs) and sulphatases, respective-
ly, both of which result in the lysosomal accumulation of GAGs. Similar
to glycogenoses, these lysosomal storage diseases are characterised by
an accumulation of autophagosomes as a result of defective
autophagosome-lysosome fusion [178]. In vitromouse models of MSD,
with knock-out of the sulphatase modifying factor 1 (Sumf1) have
identified that its knock-out leads to an accumulation of cholesterol in
lysosomal membranes which perturbs SNARE proteins and thus fusion
capabilities of the lysosomes [179]. Specific knock-out of sumf1 in astro-
cytes can cause neurodegenerative phenotypes [180], in osteoclasts
causes reduced cell survival [181] and reduced mitophagy due to
Fig. 3.Defective autophagy inNiemann–PickDisease TypeC as a target for therapeutic intervention: A— the disease is characterised by a block in autophagicfluxarising from the impaired
formation of amphisomes, in turn caused by a failure in the SNARE machinery that is required for the fusion between autophagosomes and late endosomes. B — a combination of
cholesterol releasing agent cyclodextrin with autophagy-inducing drugs has been proposed as a potential therapeutic intervention (see text for further details). The bold green arrows
represent the mechanisms allowing to overcome the defects in autolysosomal pathway in Niemann–Pick Disease Type C by inducers of autophagy (e.g. rapamycin) and cyclodextrin.
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these models is an attractive therapeutic option that requires further
investigation.
6.6. Niemann–Pick disease
Niemann–Pick disease is a group of inherited, metabolic, lipid/lyso-
somal storage disorders comprised of Niemann–Pick types A (NPA), B
(NPB) and C (NPC) disease. NPA and NPB disease are caused by muta-
tions in SMPD1 gene encoding sphingomyelin phosphodiesterase 1,
which leads to insufficient activity of the enzyme acid sphingo-
myelinase (ASM) and an accumulation of sphingomyelin [183,184].
NPC disease is caused by the mutations in NPC1 or NPC2 gene encoding
proteins essential for cholesterol efflux from the late endosomal/lysosomal compartments and leads to a build-up of cholesterol in
these compartments [185–187]. NPC1 is the most common form in
this class of diseases that primarily affects children. NPA is primarily a
severe neurologic disease-causing brain damage whereas NPB is
associated with enlarged liver and spleen (hepatosplenomegaly) and
respiratory problems [188]. NPC on the other hand is associated with
hepatomegaly, splenomegaly, psychomotor retardation and neurode-
generation along with other neurological symptoms [189].
Studies in NPC1 patient fibroblasts, NPC knock-out iPSC and
Npc1−/−mousemodels have highlighted a potential role for autophagy
in NPC1 disease. Specifically, accumulation of autophagosomes/LC3-II,
autophagic multivesicular structures, lysosomes and cathepsin D has
been observed in the brain and neuronal cultures of NPC1 mutant
mice (Npc1−/−), NPC1 patient fibroblasts, and in human embryonic
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190–194]. Although some of these studies have implied the accumula-
tion of autophagosomes as a result of autophagy induction, later studies
have defined this phenotype to be caused by a block in autophagic flux.
We have recently shown that the defect in autophagy in cells from
Npc1−/− mice is caused by the impaired formation of amphisomes
which results from a failure in the SNAREmachinery required for the fu-
sion of autophagosomes and late endosomes [161] (Fig. 3). We further
confirmed dysfunctional autophagic flux in NPC1 patient-specific
iPSC-derived neuronal and hepatic cells, which are the two primary
disease-affected cell types [161]. A separate study has also demonstrat-
ed that accumulation of lysosomal cholesterol causes aberrant seques-
tration of SNARE proteins and disrupts the fusion events between
autophagosomes with late endosomes and lysosomes [179] (Fig. 3).
Consequently, the clearance of autophagic cargo is diminished as evi-
dent from the build-up of p62 and damaged mitochondria [194–196].
A recent study has suggested another potential mechanism that may
underlie the impairment in autophagy observed inNPC1which is linked
to reduced sphingosine kinase activity and lowered levels of vascular
endothelial growth factor (VEGF). The result is an inhibition of
autophagosome maturation via abnormal sphingosine accumulation
[197]. These defects in autophagic flux have been suggested to cause
cellular toxicity in NPC1 mouse and iPSC models [161,193,195,197,
198]. In addition, lipids such as cholesterol are cleared through autoph-
agy as evident by its elevated levels in autophagy-deficient (Atg5−/−)
cells that recapitulates NPC1 cellular phenotype [80]. Our data imply
that defective autophagy arising due to NPC1mutations is likely to act
as a positive feedback loop in increasing cholesterol load, thus augment-
ing the disease phenotype [196,199].
Studies on perturbations in autophagy as an underlying factor in
NPA and NPB disease pathology are limited. A recent study has shown
accumulation of sphingomyelin and autophagosomes in neurons from
ASM knockout mice and NPA patient fibroblasts, an effect that can be
partially reversed by inhibition of sphingolipid synthesis with
Fumonisin B1. The defect in autophagy was attributed to improper
clearance of autolysosomes due to sphingomyelin-induced lysosomal
membrane permeabilisation that leads to cytosolic release of its
\proteases [200]. Age-dependent retinal degeneration was also found
in ASM knockout mice which was associated with a build-up of
autophagosomes, possibility implicating a role of defective autophagy
in the degenerative process [201].
A number of therapeutic strategies have been shown for NPC1
disease. Miglustat, an inhibitor of glycosphingolipid synthesis has been
approved for the treatment of NPC disease as a substrate reduction
approach and it has been shown to delay disease progression in trans-
genic mice [202,203]. Other avenues reported are the use of the
neurosteroid, allopregnanolone and replenishment of VEGF that were
beneficial in NPC1 mouse and iPSC models, respectively [191,197].
Hydroxypropyl-β-cyclodextrin (HPβCD), which promotes cholesterol-
release from lysosomal compartments, has also been identified as a
therapeutic candidate to treat NPC1 disease [194,204–207] (Fig. 3). A
small scale trial of treatmentwith HPβCD showed phenotypic improve-
ment, however there were issues with drug delivery though the blood
brain barrier [208]. Although treatment with HPβCD lowered cholester-
ol accumulation, it had some adverse side effects in animals [209].
Moreover, high doses of this compound had a negative impact on au-
tophagic flux and neurotoxic effects that could exacerbate the disease
phenotype [195,196,210]. On the other hand, we showed that stimulat-
ing autophagy could bypass the autophagic block at the amphisomes
stage by causing autophagosomes to directly fuse with the lysosomes,
thus restoring autophagic flux and enabling the clearance of accumulat-
ed autophagic cargo. Although, of note, restoration of autophagic flux
had negligible effect on lysosomal cholesterol. We found that stimulat-
ing autophagy with rapamycin (mTOR inhibitor) or carbamazepine (an
inositol-lowering agent and mTOR-independent autophagy inducer)
rescued the autophagy defects and improved cell viability in NPC1iPSC-derived neuronal and hepatic cells; however, certain autophagy-
inducing compounds such as trehalose, verapamil and BRD5631 were
effective only in neurons [195,196,211]. Although a study has indicated
impaired lysosomal proteolysis in NPC1 patient fibroblasts [212], our
data and other reports imply that the functionality of lysosomes and
cathepsin activity are not compromised [190,191,195,196]. We have
proposed a combination treatment strategy using lower doses of
HPβCD(that partially reduce cholesterolwithout perturbing autophagic
flux) coupled with autophagy stimulators (for restoring autophagic
flux) to abrogate the abnormal cholesterol and autophagy phenotypes
[195,196,199] (Fig. 3). Interestingly, a recent study has developed
polymeric supermolecules designed to deliver prodrugs into cells called
β-cyclodextrin-threaded biocleavable polyrotaxanes [213,214]. These
were able to reduce both the cholesterol and autophagy defects in
NPC1 patient fibroblasts [215]. In future, it would be interesting to
assess the protective effects of this compound or autophagy enhancers
and combinatorial treatments in NPC1 models in vivo.
6.7. Mucolipidosis type IV
Mucolipidosis type IV (MLIV) is a neurodegenerative lipid/lysosomal
storage disorder; the most common symptoms include ocular aberra-
tions, progressive mental defects and motor deterioration [216–218].
MLIV is caused by mutations in the MCOLN1 gene, which encodes a
transient receptor potential cation channel called mucolipin-1
(TRPML1) which is involved in calcium signalling and transport
[219–221].
A number of studies have implicated a role forMCOLN1 in lysosomal
acidification and secretion, autophagosome maturation and mitochon-
drial turnover [222–225]. Thus, disease-causing mutations inMCOLN1
are likely to impact on the autophagy pathway. Indeed, MLIV patient fi-
broblasts exhibit an accumulation of autophagosomes and p62, suggest-
ing there is a block in autophagic flux [225]. Likewise, impairment in
autophagic flux associated with accumulation of LC3-II, LAMP1, p62,
polyubiquitinated proteins and membranous intracytoplasmic storage
bodies was seen in MCOLN1-deficient mouse neurons generated from
the cerebrum of theMcoln1−/− embryos [226]. Consequently, defective
mitochondrial recycling through the autophagy pathway and increased
mitochondrial fragmentation has been shown in MLIV patient
fibroblasts [223]. Over-acidified lysosomes were also observed in MLIV
patient fibroblasts that led to the malfunction of acidic lipase activity
and lipid hydrolysis, which could be rescued by treatment with
nigericin (an H+/K+ exchange ionophore) or chloroquine (accumu-
lates in acidic spaces and dissipates low pH) [222]. A Drosophilamodel
of MLIV, which exhibited key disease phenotypes such as intracellular
accumulation of macromolecules, motor defects, and neurodegenera-
tion, was characterised by defective autophagy that resulted in oxida-
tive stress and improper clearance of apoptotic cells [227]. Moreover,
impairment in CMA has been reported in MLIV patient fibroblasts
wherein TRPML1 interacts with the chaperone proteins, Hsc70 and
Hsc40 [228]. However, further studies will be of interest to understand
the mechanistic details of how this protein regulates CMA, and how
deregulation of this process contributes to the disease pathogenesis.
There are currently no treatments for MLIV although a small
molecule, MK6-83 has been recently identified that was able to restore
the function of the defective TRPML1 channel and rescue the disease-
associated abnormalities in MLIV patient fibroblasts with specific
point mutations [229]. While this provides a promising avenue for
treatment, the therapeutic effect of autophagy modulation by small
molecules is currently unknown.
6.8. Neuronal ceroid lipofuscinosis
Neuronal ceroid lipofuscinosis (NCL) is a family of genetically dis-
tinct neurodegenerative, lysosomal storage disorders affecting young
children [230]. Symptoms include impaired vision, seizures, mental
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232]. The older classification of NCL is based upon the age of onset,
such as early infantile (Santavuori-Haltia disease), late infantile
(Jansky–Bielschowsky disease), juvenile (Batten disease) and adult
(Kufs disease) forms, whereas the newer classification is divided by
the 13 associated genes identified so far [161,233].
NCL exhibits abnormal accumulation of lipofuscin, which are
lipopigments made up of fats and proteins, in neuronal cells and other
tissues [234]. Initial studies have shown an accumulation of lysosomal
ceroid lipofuscin and autophagosomes in the neurons of mice deficient
for lysosomal proteases, cathepsin D or cathepsins B and L, implicating
that cathepsin-deficient mouse could be used for studying the
pathogenesis of NCL [235,236]. A subsequent study has shown that
mice deficient for both cathepsin D and Bax (a pro-apoptotic protein)
displayed defective autophagy and a neurodegenerative phenotype,
with the absence of caspase 3 activation, suggesting that neuronal cell
death may be caused by genetic disruption of lysosomal function and
possibly by autophagy dysfunction [237]. In addition, disruption of
autophagy associated with defective autophagosome maturation was
found in a knock-in mouse model of Batten disease (Cln3Δex7/8 mice),
the most common form of NCL (NCL3) which is caused by mutations
in CLN3 that encodes an endosomal/lysosomalmembrane protein called
CLN3 or battenin [238,239]. Likewise, accumulation of mitochondrial
ATPase subunit C protein in autophagosomal/lysosomal compartments
in NCL3 mouse and human iPSC models suggests defective mitochon-
drial turnover through the autophagy pathway [236,239–241]. An
elevation in the levels of α-synuclein oligomers and gangliosides GM1,
GM2, and GM3 was also found in NCL3 patient lymphoblast cells
[242]. Furthermore, age-dependent elevation in LC3-II, p62 aggregates
and ubiquitinated proteins were found in the brain of NCL6 mouse
model (Cln6-defective nclf mice) [243], as well as accumulation of
autophagic vacuoles seen in NCL6 patient fibroblasts [244]. A chemical
screen in a cellular model of NCL3 (Cln3Δex7/8), stably expressing GFP-
LC3 has identified that the autophagy blocker, thapsigargin causes
enhanced Ca2+ sensitivity that may lead to aberrant Ca2+ signalling
and vesicular trafficking defects [245]. Moreover, impairment in actin-
dependent processes through deregulated ARF1-Cdc42 pathway in
CLN3 mutant cells may contribute to defective vesicular trafficking
events including autophagy [246].
There is currently no cure for NCL. Treatment of the disease is based
around alleviating the symptoms caused by the neurodegeneration.
However, gene delivery through adenoviral vectors to replace the
deficient CLN2 gene was successfully demonstrated in rats and non-
human primates [247]. Due to the success of these animal trials, a
small scale clinical trial showed a small but non-significant improve-
ment [248]. Clearly there are safety issues with using viruses as gene
delivery targets. Interestingly, autophagy enhancers such as lithium
and L-690,330 (inositol monophosphatase inhibitors) [67] were
shown to reduce the abnormal accumulation of autophagosomes,
mitochondrial ATP synthase subunit C and lipofuscin in Cln3 mutant
knock-in cerebellar cells [161]. This study points to the need for a
deeper understanding of the mechanisms of defective autophagy and
its therapeutic application in NCL.7. Conclusions
While in recent years an important role of autophagy in the
maintenance of lipo-homeostasis has been revealed, the contribu-
tion of autophagy pathways to the pathology in many lipid storage
disorders still remains poorly understood. Further work will be
required to better define the mechanistic details of autophagy
perturbations in each specific disease and their contribution to the
pathology. These studies will undoubtedly inform new treatment
strategies as has already been demonstrated in case of several lipid
storage disorders.Conflict of Interest
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